Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
11.40
+1.47 (14.80%)
At close: Dec 20, 2024, 4:00 PM
11.55
+0.15 (1.32%)
After-hours: Dec 20, 2024, 5:00 PM EST
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ATRA stock have an average target of 26.5, with a low estimate of 11 and a high estimate of 57.5. The average target predicts an increase of 132.46% from the current stock price of 11.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ATRA stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Total | 7 | 6 | 6 | 6 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +119.30% | Dec 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $21 | Strong Buy | Maintains | $13 → $21 | +84.21% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 21, 2024 |
| Mizuho | Mizuho | Hold → Buy Upgrades $25 → $18 | Hold → Buy | Upgrades | $25 → $18 | +57.89% | Aug 16, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +14.04% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
125.92M
from 8.57M
Increased by 1,368.80%
Revenue Next Year
101.16M
from 125.92M
Decreased by -19.66%
EPS This Year
-8.51
from -65.18
EPS Next Year
-5.45
from -8.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 143.2M | 140.7M | 153.4M | |||
| Avg | 125.9M | 101.2M | 74.2M | |||
| Low | 109.8M | 54.9M | 3.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1,570.4% | 11.7% | 51.6% | |||
| Avg | 1,368.8% | -19.7% | -26.6% | |||
| Low | 1,180.2% | -56.4% | -96.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.34 | 2.06 | -0.82 | ||
| Avg | -8.51 | -5.45 | -5.37 | ||
| Low | -14.17 | -12.39 | -7.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.